Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Down 46.5% in December

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 27,800 shares, a decline of 46.5% from the November 30th total of 52,000 shares. Based on an average daily volume of 276,600 shares, the short-interest ratio is presently 0.1 days.

Biodexa Pharmaceuticals Stock Performance

NASDAQ:BDRX traded down $0.41 during mid-day trading on Friday, hitting $4.29. 18,151 shares of the company traded hands, compared to its average volume of 144,341. The company has a fifty day moving average of $5.05. Biodexa Pharmaceuticals has a one year low of $3.50 and a one year high of $74.00.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.